| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, December 3, 2018 Regeneron’s CD20xCD3 bispecific antibody has achieved an 80% complete response rate in a small trial of patients with relapsed or refractory follicular lymphoma. The strong early signs of efficacy led Regeneron to target a 2019 start date for a potentially registrational phase 2 study. |
|
|
Top Stories Of The Week Monday, December 3, 2018 While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and reap billions in additional sales in new market segments. Friday, November 30, 2018 With a critical shareholder vote looming next week, Takeda's CFO says the company will consider selloffs of up to $10 billion to help fund its Shire buy, which is twice as much as had been reported previously. Friday, November 30, 2018 A phase 2a trial of AstraZeneca’s AZD1419 has missed its primary endpoint. AstraZeneca moved the Dynavax-partnered TLR9 agonist into the trial in the belief it could improve time to loss of asthma control in patients with eosinophilic, moderate-to-severe forms of the disease. Friday, November 30, 2018 At the closely watched American Society of Hematology annual meeting, Fate Therapeutics will present preclinical data on three investigational cell therapies the company is developing as off-the-shelf therapies. Fate's method of producing cancer-fighting cells from stem cells could sidestep the high costs associated with personalized CAR-T therapies, the company's executives argue. Sunday, December 2, 2018 Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick. Wednesday, December 5, 2018 Australian researchers at the University of Queensland have discovered a unique DNA structure that appears to be shared by many cancers and could be used to develop a simple diagnostic test that could be performed in under 10 minutes with the naked eye. Monday, December 3, 2018 A judge ruled that Teva must face a lawsuit alleging age and anti-American discrimination in September, and now plaintiff Stephen Middlebrook has won a $6.3 million verdict. Tuesday, December 4, 2018 Several years back, Bayer was feeling so good about the future of its hemophilia treatments that it announced plans to invest $700 million in two plants in Germany and hire 500 workers by 2020. Fast-forward four years, and one of those plants will soon be closed and hundreds of workers let go. Tuesday, December 4, 2018 To help prepare the post-Brexit U.K.—and potentially the world—for future disease outbreaks, the U.K. government, with help from academic institutions and the pharma industry, is building the country’s first vaccines manufacturing and innovation center. Wednesday, December 5, 2018 German pharma giant Merck is poised to expand its R&D facilities in China next year in an effort to support development within the growing market segment. | This week's sponsor is FierceBiotech. | |  | |
Resources Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
